The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Adalimumab Injection Market Research Report 2025
Synopsis
Global Adalimumab Injection market is projected to reach US$ 1324.3 million in 2029, increasing from US$ 910 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Adalimumab Injection market research.
Key manufacturers engaged in the Adalimumab Injection industry include AbbVie, Amgen, Sandoz, Fresenius Kabi, Biogen, Celltrion, Cadila Pharmaceuticals, Bio-Thera Solutions, Ltd. and Hisun Biopharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Adalimumab Injection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Adalimumab Injection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Adalimumab Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AbbVie
Amgen
Sandoz
Fresenius Kabi
Biogen
Celltrion
Cadila Pharmaceuticals
Bio-Thera Solutions, Ltd.
Hisun Biopharmaceutical
Innovent Biologics
Mylan
Zydus Group
Boehringer Ingelheim
Jiangsu Chia Tai-Tianqing Pharmaceutical
Shanghai Henlius Biotech
Segment by Type
40mg/0.8ml
20mg/0.4ml
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Adalimumab Injection report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Global Adalimumab Injection market is projected to reach US$ 1324.3 million in 2029, increasing from US$ 910 million in 2022, with the CAGR of 5.6% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Adalimumab Injection market research.
Key manufacturers engaged in the Adalimumab Injection industry include AbbVie, Amgen, Sandoz, Fresenius Kabi, Biogen, Celltrion, Cadila Pharmaceuticals, Bio-Thera Solutions, Ltd. and Hisun Biopharmaceutical, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Adalimumab Injection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Adalimumab Injection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Adalimumab Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AbbVie
Amgen
Sandoz
Fresenius Kabi
Biogen
Celltrion
Cadila Pharmaceuticals
Bio-Thera Solutions, Ltd.
Hisun Biopharmaceutical
Innovent Biologics
Mylan
Zydus Group
Boehringer Ingelheim
Jiangsu Chia Tai-Tianqing Pharmaceutical
Shanghai Henlius Biotech
Segment by Type
40mg/0.8ml
20mg/0.4ml
Segment by Application
Hospitals
Clinics
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Adalimumab Injection report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Adalimumab Injection Market Overview
1.1 Product Overview and Scope of Adalimumab Injection
1.2 Adalimumab Injection Segment by Type
1.2.1 Global Adalimumab Injection Market Value Comparison by Type (2023-2029)
1.2.2 40mg/0.8ml
1.2.3 20mg/0.4ml
1.3 Adalimumab Injection Segment by Application
1.3.1 Global Adalimumab Injection Market Value by Application: (2023-2029)
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Global Adalimumab Injection Market Size Estimates and Forecasts
1.4.1 Global Adalimumab Injection Revenue 2018-2029
1.4.2 Global Adalimumab Injection Sales 2018-2029
1.4.3 Global Adalimumab Injection Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Adalimumab Injection Market Competition by Manufacturers
2.1 Global Adalimumab Injection Sales Market Share by Manufacturers (2018-2023)
2.2 Global Adalimumab Injection Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Adalimumab Injection Average Price by Manufacturers (2018-2023)
2.4 Global Adalimumab Injection Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Adalimumab Injection, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Adalimumab Injection, Product Type & Application
2.7 Adalimumab Injection Market Competitive Situation and Trends
2.7.1 Adalimumab Injection Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Adalimumab Injection Players Market Share by Revenue
2.7.3 Global Adalimumab Injection Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Adalimumab Injection Retrospective Market Scenario by Region
3.1 Global Adalimumab Injection Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Adalimumab Injection Global Adalimumab Injection Sales by Region: 2018-2029
3.2.1 Global Adalimumab Injection Sales by Region: 2018-2023
3.2.2 Global Adalimumab Injection Sales by Region: 2024-2029
3.3 Global Adalimumab Injection Global Adalimumab Injection Revenue by Region: 2018-2029
3.3.1 Global Adalimumab Injection Revenue by Region: 2018-2023
3.3.2 Global Adalimumab Injection Revenue by Region: 2024-2029
3.4 North America Adalimumab Injection Market Facts & Figures by Country
3.4.1 North America Adalimumab Injection Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Adalimumab Injection Sales by Country (2018-2029)
3.4.3 North America Adalimumab Injection Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Adalimumab Injection Market Facts & Figures by Country
3.5.1 Europe Adalimumab Injection Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Adalimumab Injection Sales by Country (2018-2029)
3.5.3 Europe Adalimumab Injection Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Adalimumab Injection Market Facts & Figures by Country
3.6.1 Asia Pacific Adalimumab Injection Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Adalimumab Injection Sales by Country (2018-2029)
3.6.3 Asia Pacific Adalimumab Injection Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Adalimumab Injection Market Facts & Figures by Country
3.7.1 Latin America Adalimumab Injection Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Adalimumab Injection Sales by Country (2018-2029)
3.7.3 Latin America Adalimumab Injection Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Adalimumab Injection Market Facts & Figures by Country
3.8.1 Middle East and Africa Adalimumab Injection Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Adalimumab Injection Sales by Country (2018-2029)
3.8.3 Middle East and Africa Adalimumab Injection Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Adalimumab Injection Sales by Type (2018-2029)
4.1.1 Global Adalimumab Injection Sales by Type (2018-2023)
4.1.2 Global Adalimumab Injection Sales by Type (2024-2029)
4.1.3 Global Adalimumab Injection Sales Market Share by Type (2018-2029)
4.2 Global Adalimumab Injection Revenue by Type (2018-2029)
4.2.1 Global Adalimumab Injection Revenue by Type (2018-2023)
4.2.2 Global Adalimumab Injection Revenue by Type (2024-2029)
4.2.3 Global Adalimumab Injection Revenue Market Share by Type (2018-2029)
4.3 Global Adalimumab Injection Price by Type (2018-2029)
5 Segment by Application
5.1 Global Adalimumab Injection Sales by Application (2018-2029)
5.1.1 Global Adalimumab Injection Sales by Application (2018-2023)
5.1.2 Global Adalimumab Injection Sales by Application (2024-2029)
5.1.3 Global Adalimumab Injection Sales Market Share by Application (2018-2029)
5.2 Global Adalimumab Injection Revenue by Application (2018-2029)
5.2.1 Global Adalimumab Injection Revenue by Application (2018-2023)
5.2.2 Global Adalimumab Injection Revenue by Application (2024-2029)
5.2.3 Global Adalimumab Injection Revenue Market Share by Application (2018-2029)
5.3 Global Adalimumab Injection Price by Application (2018-2029)
6 Key Companies Profiled
6.1 AbbVie
6.1.1 AbbVie Corporation Information
6.1.2 AbbVie Description and Business Overview
6.1.3 AbbVie Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.1.4 AbbVie Adalimumab Injection Product Portfolio
6.1.5 AbbVie Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Amgen Adalimumab Injection Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Sandoz
6.3.1 Sandoz Corporation Information
6.3.2 Sandoz Description and Business Overview
6.3.3 Sandoz Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sandoz Adalimumab Injection Product Portfolio
6.3.5 Sandoz Recent Developments/Updates
6.4 Fresenius Kabi
6.4.1 Fresenius Kabi Corporation Information
6.4.2 Fresenius Kabi Description and Business Overview
6.4.3 Fresenius Kabi Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Fresenius Kabi Adalimumab Injection Product Portfolio
6.4.5 Fresenius Kabi Recent Developments/Updates
6.5 Biogen
6.5.1 Biogen Corporation Information
6.5.2 Biogen Description and Business Overview
6.5.3 Biogen Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Biogen Adalimumab Injection Product Portfolio
6.5.5 Biogen Recent Developments/Updates
6.6 Celltrion
6.6.1 Celltrion Corporation Information
6.6.2 Celltrion Description and Business Overview
6.6.3 Celltrion Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Celltrion Adalimumab Injection Product Portfolio
6.6.5 Celltrion Recent Developments/Updates
6.7 Cadila Pharmaceuticals
6.6.1 Cadila Pharmaceuticals Corporation Information
6.6.2 Cadila Pharmaceuticals Description and Business Overview
6.6.3 Cadila Pharmaceuticals Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Cadila Pharmaceuticals Adalimumab Injection Product Portfolio
6.7.5 Cadila Pharmaceuticals Recent Developments/Updates
6.8 Bio-Thera Solutions, Ltd.
6.8.1 Bio-Thera Solutions, Ltd. Corporation Information
6.8.2 Bio-Thera Solutions, Ltd. Description and Business Overview
6.8.3 Bio-Thera Solutions, Ltd. Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Bio-Thera Solutions, Ltd. Adalimumab Injection Product Portfolio
6.8.5 Bio-Thera Solutions, Ltd. Recent Developments/Updates
6.9 Hisun Biopharmaceutical
6.9.1 Hisun Biopharmaceutical Corporation Information
6.9.2 Hisun Biopharmaceutical Description and Business Overview
6.9.3 Hisun Biopharmaceutical Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Hisun Biopharmaceutical Adalimumab Injection Product Portfolio
6.9.5 Hisun Biopharmaceutical Recent Developments/Updates
6.10 Innovent Biologics
6.10.1 Innovent Biologics Corporation Information
6.10.2 Innovent Biologics Description and Business Overview
6.10.3 Innovent Biologics Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Innovent Biologics Adalimumab Injection Product Portfolio
6.10.5 Innovent Biologics Recent Developments/Updates
6.11 Mylan
6.11.1 Mylan Corporation Information
6.11.2 Mylan Adalimumab Injection Description and Business Overview
6.11.3 Mylan Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Mylan Adalimumab Injection Product Portfolio
6.11.5 Mylan Recent Developments/Updates
6.12 Zydus Group
6.12.1 Zydus Group Corporation Information
6.12.2 Zydus Group Adalimumab Injection Description and Business Overview
6.12.3 Zydus Group Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.12.4 Zydus Group Adalimumab Injection Product Portfolio
6.12.5 Zydus Group Recent Developments/Updates
6.13 Boehringer Ingelheim
6.13.1 Boehringer Ingelheim Corporation Information
6.13.2 Boehringer Ingelheim Adalimumab Injection Description and Business Overview
6.13.3 Boehringer Ingelheim Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Boehringer Ingelheim Adalimumab Injection Product Portfolio
6.13.5 Boehringer Ingelheim Recent Developments/Updates
6.14 Jiangsu Chia Tai-Tianqing Pharmaceutical
6.14.1 Jiangsu Chia Tai-Tianqing Pharmaceutical Corporation Information
6.14.2 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Description and Business Overview
6.14.3 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Jiangsu Chia Tai-Tianqing Pharmaceutical Adalimumab Injection Product Portfolio
6.14.5 Jiangsu Chia Tai-Tianqing Pharmaceutical Recent Developments/Updates
6.15 Shanghai Henlius Biotech
6.15.1 Shanghai Henlius Biotech Corporation Information
6.15.2 Shanghai Henlius Biotech Adalimumab Injection Description and Business Overview
6.15.3 Shanghai Henlius Biotech Adalimumab Injection Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Shanghai Henlius Biotech Adalimumab Injection Product Portfolio
6.15.5 Shanghai Henlius Biotech Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Adalimumab Injection Industry Chain Analysis
7.2 Adalimumab Injection Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Adalimumab Injection Production Mode & Process
7.4 Adalimumab Injection Sales and Marketing
7.4.1 Adalimumab Injection Sales Channels
7.4.2 Adalimumab Injection Distributors
7.5 Adalimumab Injection Customers
8 Adalimumab Injection Market Dynamics
8.1 Adalimumab Injection Industry Trends
8.2 Adalimumab Injection Market Drivers
8.3 Adalimumab Injection Market Challenges
8.4 Adalimumab Injection Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
